Apollo Endosurgery Inc (APEN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Apollo Endosurgery Inc (APEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10041
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Apollo Endosurgery Inc (Apollo Endo), formerly Lpath Inc, is a medical technology company that designs, develops and commercializes medical devices used for the treatment of obesity. The company’s product portfolio comprises endo-bariatric products such as Orbera Intragastric Balloon System and OverStitch endoscopic suturing system; and Lap-Band system for laparoscopic bariatric surgeries. These surgical and non-surgical interventional devices are also used in procedures that address or repair a variety of gastrointestinal defects. Apollo Endo’s products are used by bariatric surgeons, general surgeons and gastroenterologists. It has a manufacturing facility in the Coyol Free Trade Zone in Alajuela, Costa Rica. Apollo Endo is headquartered in Austin, Texas, the US.

Apollo Endosurgery Inc (APEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 11
Merger 13
Lpath and Apollo Endosurgery Merges 13
Equity Offering 14
Apollo Endosurgery Raises USD23.7 Million in Public Offering of Shares 14
Apollo Endosurgery to Raise up to USD16 Million in Public Offering of Shares 15
Apollo Endosurgery Raises USD36 Million in Public Offering of Shares 16
Lpath Raises USD12.5 Million in Private Placement of Shares 18
Lpath Files Registration Statement For Public Offering Of Class A Common Stock For Up To US$20 Million 20
Lpath Files Registration Statement For Public Offering Of Securities For Up To US$40 Million 21
Lpath Completes Public Offering Of Shares For US$12 Million 22
Lpath Announces Public Offering Of Class A Common Stock For US$9.3 Million 23
Asset Transactions 24
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 24
Apollo Endosurgery Inc – Key Competitors 25
Apollo Endosurgery Inc – Key Employees 26
Apollo Endosurgery Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 08, 2018: Apollo Endosurgery reports second quarter 2018 results 28
May 03, 2018: Apollo Endosurgery Reports First Quarter 2018 Results 30
Mar 01, 2018: Apollo Endosurgery Reports Fourth Quarter and Full Year 2017 Results 31
Oct 26, 2017: Apollo Endosurgery Reports Third Quarter 2017 Results 33
Aug 01, 2017: Apollo Endosurgery Reports Second Quarter 2017 Results 35
Jul 12, 2017: Apollo Endosurgery Reports Preliminary Unaudited Financial Estimates for the Second Quarter of 2017 37
May 04, 2017: Apollo Endosurgery Reports First Quarter 2017 Results 38
Mar 08, 2017: Apollo Endosurgery Reports Fourth Quarter and Full Year 2016 Results 39
Corporate Communications 41
May 31, 2018: Apollo Endosurgery Appoints Dr. Julie Shimer to Board of Directors 41
Nov 16, 2017: David C. Pacitti Joins Apollo Endosurgery Board of Directors 42
Jan 17, 2017: Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer 43
Government and Public Interest 44
Jun 25, 2018: Two diabetes medications don’t slow progression of type 2 diabetes in youth 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 11
Lpath and Apollo Endosurgery Merges 13
Apollo Endosurgery Raises USD23.7 Million in Public Offering of Shares 14
Apollo Endosurgery to Raise up to USD16 Million in Public Offering of Shares 15
Apollo Endosurgery Raises USD36 Million in Public Offering of Shares 16
Lpath Raises USD12.5 Million in Private Placement of Shares 18
Lpath Files Registration Statement For Public Offering Of Class A Common Stock For Up To US$20 Million 20
Lpath Files Registration Statement For Public Offering Of Securities For Up To US$40 Million 21
Lpath Completes Public Offering Of Shares For US$12 Million 22
Lpath Announces Public Offering Of Class A Common Stock For US$9.3 Million 23
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 24
Apollo Endosurgery Inc, Key Competitors 25
Apollo Endosurgery Inc, Key Employees 26
Apollo Endosurgery Inc, Other Locations 27
Apollo Endosurgery Inc, Subsidiaries 27

List of Figures
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Apollo Endosurgery Inc (APEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dance Biopharm Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Dance Biopharm Inc (Dance Biopharm), a subsidiary of Dance Biopharm Holdings Inc, formerly Dance Pharmaceuticals Inc, is a biotechnology company that develops inhaled insulin products to treat diabetes patients. The company provides product pipeline such as Dance-501, a pocket-sized inhaler …
  • Impel NeuroPharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Impel NeuroPharma Inc (Impel) is a clinical-stage biotechnology company that which develops intranasal drug treatments for central nervous system disorders. The company’s product pipeline includes INP104, INP103, INP102, INP101, INP105, and INP106. It also develops Precision Olfactory Delive …
  • The E. W. Scripps Company (SSP):企業の財務・戦略的SWOT分析
    The E. W. Scripps Company (SSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Cytox Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Cytox Ltd (Cytox) is a diagnostic and prognostic service provider that develops services for neurodegenerative disorders. The company’s blood tests are used to predict, which patients with MCI will develop Alzheimer's disease. Its biomarkers are based on the cell cycle hypothesis of Alzheime …
  • Schaffer Corporation Limited (SFC):企業の財務・戦略的SWOT分析
    Schaffer Corporation Limited (SFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Universal Biosensors Inc (UBI):企業の財務・戦略的SWOT分析
    Universal Biosensors Inc (UBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Omnicom Group, Inc.:企業の戦略・SWOT・財務情報
    Omnicom Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Omnicom Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • American Axle & Manufacturing Holdings, Inc.:企業の戦略・SWOT・財務情報
    American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • GC Pharma (006280):製薬・医療:M&Aディール及び事業提携情報
    Summary GC Pharma(GC Pharma) formerly known as Green Cross Corp, a subsidiary of Green Cross Holdings Corp provides plasma protein therapeutics and vaccines. The company develops, manufactures and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and a …
  • Canadian National Railway Co:戦略・SWOT・企業財務分析
    Canadian National Railway Co - Strategy, SWOT and Corporate Finance Report Summary Canadian National Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • IntegraGen SA (ALINT):医療機器:M&Aディール及び事業提携情報
    Summary IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis …
  • Arcelik A.S. (ARCLK):企業の財務・戦略的SWOT分析
    Arcelik A.S. (ARCLK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Techtronic Industries Co Ltd (669)
    Techtronic Industries Co Ltd (669) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Veridian Corporation:発電所・企業SWOT分析
    Veridian Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • Numab Innovation AG-製薬・医療分野:企業M&A・提携分析
    Summary Numab Innovation AG (Numab) designs and develops novel therapeutics for the treatment of severe diseases. The company’s lead program ND007, a bispecific antibody fragment which is being evaluated for the treatment of autoimmune diseases. Numab’s other pipeline drug candidates include ND009, …
  • Nutreco N.V.:企業の戦略・SWOT・財務情報
    Nutreco N.V. - Strategy, SWOT and Corporate Finance Report Summary Nutreco N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Titan Pharmaceuticals Inc (TTNP):医療機器:M&Aディール及び事業提携情報
    Summary Titan Pharmaceuticals Inc (Titan) is a pharmaceutical company that develops therapeutics for the treatment of serious medical disorders. The company develops drugs using ProNeura, a proprietary drug delivery platform, for the treatment of chronic diseases. It product portfolio provides probu …
  • Culture Landmark Investment Ltd
    Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Virginia Electric and Power Co:企業の戦略的SWOT分析
    Virginia Electric and Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Save The Children Federation Inc:企業の戦略的SWOT分析
    Save The Children Federation Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆